A detailed history of Vident Advisory, LLC transactions in Compugen LTD stock. As of the latest transaction made, Vident Advisory, LLC holds 25,296 shares of CGEN stock, worth $41,485. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,296
Previous 28,658 11.73%
Holding current value
$41,485
Previous $73.9 Million 42.52%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.68 - $2.52 $5,648 - $8,472
-3,362 Reduced 11.73%
25,296 $42.5 Million
Q1 2024

May 14, 2024

SELL
$1.75 - $2.95 $2,483 - $4,186
-1,419 Reduced 4.72%
28,658 $73.9 Million
Q4 2023

Feb 14, 2024

SELL
$0.53 - $2.0 $7,109 - $26,830
-13,415 Reduced 30.84%
30,077 $59.6 Million
Q3 2023

Feb 21, 2024

BUY
$0.88 - $1.31 $11,805 - $17,573
13,415 Added 44.6%
43,492 $40.4 Million
Q3 2023

Nov 14, 2023

BUY
$0.88 - $1.31 $38,272 - $56,974
43,492 New
43,492 $40.4 Million

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $142M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.